APPLIED THERAPEUTICS INC (APLT)
US03828A1016 - Common Stock
Overall APLT gets a fundamental rating of 2 out of 10. We evaluated APLT against 561 industry peers in the Biotechnology industry. APLT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. APLT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year APLT has reported negative net income.
APLT had a negative operating cash flow in the past year.
APLT had negative earnings in each of the past 5 years.
In the past 5 years APLT always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of APLT (-252.80%) is worse than 92.97% of its industry peers.
With a Return On Equity value of -4572.20%, APLT is not doing good in the industry: 84.50% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -252.8% | ||
| ROE | -4572.2% | ||
| ROIC | N/A |
ROA(3y)-183.57%
ROA(5y)-146.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for APLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, APLT has more shares outstanding
There is no outstanding debt for APLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
APLT has an Altman-Z score of -11.66. This is a bad value and indicates that APLT is not financially healthy and even has some risk of bankruptcy.
APLT's Altman-Z score of -11.66 is on the low side compared to the rest of the industry. APLT is outperformed by 78.02% of its industry peers.
APLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.66 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
APLT has a Current Ratio of 1.06. This is a normal value and indicates that APLT is financially healthy and should not expect problems in meeting its short term obligations.
APLT has a Current ratio of 1.06. This is amonst the worse of the industry: APLT underperforms 87.75% of its industry peers.
A Quick Ratio of 1.06 indicates that APLT should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.06, APLT is not doing good in the industry: 85.95% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
APLT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.58%.
APLT shows a decrease in Revenue. In the last year, the revenue decreased by -1.98%.
EPS 1Y (TTM)-24.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.13%
Revenue 1Y (TTM)-1.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 11.68% on average over the next years. This is quite good.
APLT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.22% yearly.
EPS Next Y-9.6%
EPS Next 2Y26.61%
EPS Next 3Y21.45%
EPS Next 5Y11.68%
Revenue Next Year-95%
Revenue Next 2Y17.58%
Revenue Next 3Y84.08%
Revenue Next 5Y66.22%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APLT. In the last year negative earnings were reported.
Also next year APLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as APLT's earnings are expected to grow with 21.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.61%
EPS Next 3Y21.45%
5. Dividend
5.1 Amount
No dividends for APLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APPLIED THERAPEUTICS INC
NASDAQ:APLT (1/8/2025, 8:00:00 PM)
Premarket: 0.7 -0.03 (-3.51%)0.7255
-0.08 (-9.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners86.37%
Inst Owner Change0%
Ins Owners5.31%
Ins Owner Change-1.82%
Market Cap84.42M
Analysts81.67
Price Target4.59 (532.67%)
Short Float %17.75%
Short Ratio2.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.93%
Min EPS beat(2)-197.84%
Max EPS beat(2)111.97%
EPS beat(4)1
Avg EPS beat(4)-110.97%
Min EPS beat(4)-311.83%
Max EPS beat(4)111.97%
EPS beat(8)3
Avg EPS beat(8)-56.25%
EPS beat(12)6
Avg EPS beat(12)-34.77%
EPS beat(16)10
Avg EPS beat(16)-23.46%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.84%
PT rev (3m)-64.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.17%
EPS NY rev (1m)-9.61%
EPS NY rev (3m)-52.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-52.99%
Revenue NY rev (1m)-59.23%
Revenue NY rev (3m)-68.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.08 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 14.33 | ||
| P/tB | 14.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.09
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -252.8% | ||
| ROE | -4572.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-183.57%
ROA(5y)-146.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | -11.66 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.13%
EPS Next Y-9.6%
EPS Next 2Y26.61%
EPS Next 3Y21.45%
EPS Next 5Y11.68%
Revenue 1Y (TTM)-1.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-95%
Revenue Next 2Y17.58%
Revenue Next 3Y84.08%
Revenue Next 5Y66.22%
EBIT growth 1Y-117.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.16%
EBIT Next 3Y38%
EBIT Next 5YN/A
FCF growth 1Y8.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.19%
OCF growth 3YN/A
OCF growth 5YN/A